Toll-like receptors pathways implication in common autoimmune diseases and therapeutic perspectives

Giornale Italiano di Dermatologia e Venereologia

Volumn 150, Issue 2, 2015, Pages 255-260

  Alexoudi, I ^a   Kapsimali, V ^b   Vaiopoulos, A ^a   Kanakis, M ^c   Vaiopoulos, G ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Autoimmunity; Lupus erythematosus; Psoriasis; Rheumatoid arthritis; Systemic; Toll like receptors

Indexed keywords

TOLL LIKE RECEPTOR; CYTOKINE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; HUMAN; IMMUNITY; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84942413631     PISSN: 03920488     EISSN: 18271820     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Jin SH, Kang HY. Activation of Toll-like Receptors 1, 2, 4, 5, and 7 on Human Melanocytes Modulate Pigmentation. Ann Dermatol 2010;22:486-9
2. Martin Mempel, Behnam Naderi Kalali. Toll-Like receptors in dermatology. Dermatol Clin 2007;531-40.
3. Kulkarni R, Behboudi S, Sharif S. Insights into the role of Tolllike receptors in modulation of T cell responses. Cell Tissue Res 2011;343:141-52.
4. Loiarro M, Capolunghi F, Fantò N, Gallo G, Campo S, Arseni B et al. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAKI and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol 2007;82:801-10.
5. Zhu J, Mohan C. Toll-like receptor signaling pathways-therapeutic opportunities. Mediators Inflamm 2010;2010:781235.
6. J Revuz, J-G Roujeau, FA Kerdel. Skin immune system, Life threatening dermatoses and emergencies in dermatology. Springer; 2009.
7. Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol 2010;87:385-95.
8. Horton CG, Pan ZJ, Farris AD. Targeting Toll-like receptors for treatment of SLE. Mediators Inflamm 2010;2010.
9. Su SB, Silver PB, Grajewski RS, Agarwal RK, Tang J, Chan CC et al. Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Thl-mediated autoimmunity. J Immunol 2005;175:6303-10.
10. Ercolini AM, Miller SD. The role of infections in autoimmune disease. Clin Exp Immunol 2009;155:1-15.
11. Vanderlugt CJ, Miller SD. Epitope spreading. Curr Opin Immunol 1996;8:831-6.
12. Isnardi I, Ng YS, Srdanovic I, Motaghedi R, Rudchenko S, von Bernuth H et al. IRAK-4-and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 2008;29:746-57.
13. Lin AC, Dissanayake D, Dhanji S, Elford AR, Ohashi PS. Different toll-like receptor stimuli have a profound impact on cytokines required to break tolerance and induce autoimmunity. PLoS One 2011;6:e23940.
14. Fang J, Fang D, Silver PB, Wen F, Li B, Ren X et al. The role of TLR2, TRL3, TRL4, and TRL9 signaling in the pathogenesis of autoimmune disease in a retinal autoimmunity model. Invest Ophthalmol Vis Sci 2010;51:3092-9.
15. Lang T, Mansell A. The negative regulation of Toll-like receptor and associated pathways. Immunol Cell Biol 2007;85:425-34.
16. Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL et al. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis 2010;69:1315-20.
17. Takagi M. Toll-like receptor-A potent driving force behind rheumatoid arthritis. J Clin Exp Hematop 2011;51:77-92.
18. Horton CG, Farris AD. Toll-like receptors in systemic lupus erythematosus: potential targets for therapeutic intervention. Curr Allergy Asthma Rep 2012;12:1-7.
19. Shotorbani SS, Su ZL, Xu HX. Toll-like receptors are potential therapeutic targets in rheumatoid arthritis. World J Biol Chem 2011;2:167-72.
20. Koh YT, Scatizzi JC, Gahan JD, Lawson BR, Baccala R, Pollard KM et al. Role of nucleic acid-sensing TLRs in diverse autoantibody specificities and anti-nuclear antibody-producing B cells. J Immunol 2013;190:4982-90.
21. Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI et al. Lupus Interferon Skin Activity (LISA) Study Investigators. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011;70:1905-13.
22. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131-9.
23. Santiago-Raber ML, Baudino L, Izui S. Emerging roles of TLR7 and TLR9 in murine SLE. J Autoimmun 2009;33:231-8.
24. Lo MS, Tsokos GC. Treatment of systemic lupus erythematosus: new advances in targeted therapy. Ann N Y Acad Sci 2012;1247:138-52.
25. Walker SL, Roberts CH, Atkinson SE, Khadge S, Macdonald M et al. The effect of systemic corticosteroid therapy on the expression of toll-like receptor 2 and toll-like receptor 4 in the cutaneous lesions of leprosy Type 1 reactions. Br J Dermatol 2012;167:29-35.
26. Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010;465:937-41.
27. Miller LS. Toll-like receptors in skin. Adv Dermatol 2008;24:71-87.
28. McLnturff JE, Modlin RL, Kim J. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. J Invest Dermatol 2005;125:1-8.
29. Jiang W, Zhu FG, Yu D, Tang JX, Kandimalla ER et al. A Toll-Like Receptor 7, 8, and 9 Antagonist inhibits Thl and Thl7 responses and inflammasome activation in a model of IL-23-induced psoriasis. J Invest Dermatol 2013.
30. Kim SK, Park S, Lee ES. Toll-like receptors and antimicrobial peptides expressions of psoriasis: correlation with serum vitamin D level. J Korean Med Sci 2010;25:1506-12.
31. De Pita O, Nardis C, Lupi F, Luci CA, Frezzolini A, Pallotta S. Modulation of Toll-like receptors in psoriatic patients during therapy with adahmumab. Int J Immunopathol Pharmacol 2011;24:185-8.
32. Morizane S, Yamasaki K, Mühleisen B, Kotol PF, Murakami M, Aoyama Y et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol 2012;132:135-43.